title: Effect of oral L-arginine administration on exhaled nitric oxide (NO) concentration in healthy volunteers.
abstract: We previously reported a case of pulmonary hypertension, where the symptoms were improved by oral L-arginine (arginine) administration. Arginine may increase nitric oxide (NO) production in the pulmonary artery. Exhaled NO may reflect pulmonary artery NO production. It has been demonstrated that exhaled NO concentration is higher in patients with allergic diseases, but whether oral arginine administration alters exhaled NO is unknown. Therefore, in this study, we investigated whether oral arginine administration increases exhaled NO among healthy volunteers with and without a history of allergy. Eleven subjects were given a single oral dose (200 mg/kg) of arginine, and their plasma arginine concentrations and exhaled NO were measured up to 150 minutes. Baseline values of exhaled NO concentration were significantly higher in those with a history of allergy (56.4±20.3 ppb, n=5, P< 0.05) than those without (16.8±4.0 ppb, n=6). Oral arginine increased exhaled NO, which peaked at 60 minutes after the administration in those with a history of allergy (85.2±44.8 ppb, n=5). However, the increase in exhaled NO was not significant compared to the baseline values. In contrast, plasma arginine concentration was increased significantly by arginine administration (P< 0.01), regardless of an allergy history. These results suggested that the difference in exhaled NO concentration was not due to a difference in arginine absorption. Serum IgE level was significantly higher in the group with a history of allergy. Eosinophils and white blood cells were within normal range in all subjects. We conclude that oral arginine administration does not significantly increase exhaled NO, regardless of allergy history. However, as arginine administration has been reported to be effective in patients with pulmonary hypertension, it will be necessary to test exhaled NO in subjects with pulmonary hypertension in the future.
authors.affiliation: Department of Pharmacology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima 960-1295, Japan. h-ogapi@fmu.ac.jp
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ogata
authors.forename: Midori
authors.initials: M
authors.lastname: Yatabe
authors.forename: Shingen
authors.initials: S
authors.lastname: Misaka
authors.forename: Yayoi
authors.initials: Y
authors.lastname: Shikama
authors.forename: Suguru
authors.initials: S
authors.lastname: Sato
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Munakata
authors.forename: Junko
authors.initials: J
authors.lastname: Kimura
mesh_terms: D000284:Administration, Oral; D000328:Adult; D001120:Arginine / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D001944:Breath Tests; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy; D007073:Immunoglobulin E / Q000097:blood; D008875:Middle Aged; D009569:Nitric Oxide / Q000032:analysis / Q000096:biosynthesis*
chemical_list: D009569:Nitric Oxide; D007073:Immunoglobulin E; D001120:Arginine